Thomas Hatschek - Publications

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.

Journal: Nature communications

Published: August 29, 2025

Prognostic and predictive implications of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) expression in breast cancer.

Journal: International journal of cancer

Published: February 07, 2024

Multiresolution Self-Supervised Feature Integration via Attention Multiple Instance Learning for Histopathology Analysis.

Journal: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference

Published: December 12, 2023

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.

Journal: Breast cancer research and treatment

Published: July 24, 2023

An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.

Journal: Molecular oncology

Published: July 11, 2023

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy.

Journal: Breast (Edinburgh, Scotland)

Published: May 21, 2023

Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer.

Journal: Nature communications

Published: May 08, 2023

CD169+ Macrophages in Primary Breast Tumors Associate with Tertiary Lymphoid Structures, Tregs and a Worse Prognosis for Patients with Advanced Breast Cancer.

Journal: Cancers

Published: January 24, 2023

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 16, 2022

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.

Journal: NPJ breast cancer

Published: March 10, 2022

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer.

Journal: Cancers

Published: July 18, 2021

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: June 24, 2021